PMID- 37394794
OWN - NLM
STAT- Publisher
LR  - 20231004
IS  - 1550-9397 (Electronic)
IS  - 1550-9389 (Print)
IS  - 1550-9389 (Linking)
VI  - 19
IP  - 7
DP  - 2023 Jul 1
TI  - Economic burden of comorbid insomnia in 5 common medical disease subgroups.
PG  - 1293-1302
LID - 10.5664/jcsm.10592 [doi]
AB  - STUDY OBJECTIVES: Approximately 85% of insomnia co-occurs with other disorders. 
      Whereas insomnia was once considered "secondary" to these disorders, it is now 
      widely recognized as an independent condition warranting treatment. While it is 
      clear that insomnia can affect the course of other medical conditions, there is 
      scant literature on the economic impact of comorbid insomnia among patients with 
      common medical conditions. The aim of this study was to determine the economic 
      burden of comorbid insomnia in 5 medical diseases commonly associated with 
      insomnia: type 2 diabetes mellitus (T2DM), cancer undergoing treatment, menopause 
      undergoing hormone replacement therapy, osteoporosis, and Alzheimer's disease and 
      related dementias (ADRDs). METHODS: This retrospective cohort study used claims 
      data from the IBM MarketScan Commercial and Medicare Supplemental Databases from 
      January 1, 2014, through December 31, 2019. Insomnia and comorbid disease groups 
      were defined using physician-assigned International Classification of Diseases 
      diagnostic codes. Insomnia medication treatment was defined based on >/=1 
      prescription fills for the most commonly prescribed insomnia medications 
      (zolpidem, low-dose trazodone, and benzodiazepines [as a class]). For each 
      comorbid disease subgroup, 4 cohorts were created: (1) patients with either 
      treated or untreated insomnia, (2) non-sleep-disordered controls, (3) patients 
      with untreated insomnia, and (4) patients with treated insomnia. RESULTS: Sample 
      sizes for individuals with comorbid insomnia ranged from 23,168 (T2DM) to 3,015 
      (ADRDs). Within each disease subgroup and relative to non-sleep-disordered 
      controls, patients with comorbid insomnia demonstrated greater adjusted health 
      care resource utilization and costs across most points of service. Likewise, 
      relative to individuals with untreated insomnia, those with treated insomnia 
      generally demonstrated greater adjusted health care resource utilization and 
      costs. CONCLUSIONS: In this national analysis, both untreated comorbid insomnia 
      and comorbid insomnia treated with commonly prescribed insomnia medications were 
      associated with increased health care resource utilization and costs across most 
      points of service. CITATION: Wickwire EM, Juday TR, Kelkar M, Heo J, Margiotta C, 
      Frech FH. Economic burden of comorbid insomnia in 5 common medical disease 
      subgroups. J Clin Sleep Med. 2023;19(7):1293-1302.
CI  - (c) 2023 American Academy of Sleep Medicine.
FAU - Wickwire, Emerson M
AU  - Wickwire EM
AD  - Sleep Disorders Center, Division of Pulmonary and Critical Care Medicine, 
      Department of Medicine, University of Maryland School of Medicine, Baltimore, 
      Maryland.
AD  - Department of Psychiatry, University of Maryland School of Medicine, Baltimore, 
      Maryland.
FAU - Juday, Timothy R
AU  - Juday TR
AD  - Eisai, Inc., Nutley, New Jersey.
FAU - Kelkar, Mona
AU  - Kelkar M
AD  - Genesis Research, Hoboken, New Jersey.
FAU - Heo, Jihaeng
AU  - Heo J
AD  - Genesis Research, Hoboken, New Jersey.
FAU - Margiotta, Caroline
AU  - Margiotta C
AD  - Genesis Research, Hoboken, New Jersey.
FAU - Frech, Feride H
AU  - Frech FH
AD  - Eisai, Inc., Nutley, New Jersey.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Clin Sleep Med
JT  - Journal of clinical sleep medicine : JCSM : official publication of the American 
      Academy of Sleep Medicine
JID - 101231977
SB  - IM
PMC - PMC10315590
OTO - NOTNLM
OT  - comorbid
OT  - costs
OT  - economics
OT  - health care utilization
OT  - insomnia
OT  - medication
COIS- All authors have reviewed and approved the manuscript. The strategic design of 
      the study was performed at Eisai Inc. Data analyses were conducted by Genesis 
      Research. Timothy Juday and Feride Frech are employees of Eisai, Inc., which 
      markets an insomnia medication. Mona Kellar, Jihaeng Heo, and Caroline Margiotta 
      are employees of Genesis Research, which conducted the statistical analyses for 
      the study. Emerson Wickwire has received research funding from the AASM 
      Foundation, US Department of Defense, Merck, ResMed, and the ResMed Foundation; 
      has served as scientific consultant to DayZz, Eisai, EnsoData, Idorsia, Merck, 
      Primasun, and Purdue; and is an equity shareholder in WellTap. Emerson Wickwire 
      received compensation for consulting on this study.
EDAT- 2023/07/03 06:41
MHDA- 2023/07/03 06:41
PMCR- 2024/07/01
CRDT- 2023/07/03 01:23
PHST- 2024/07/01 00:00 [pmc-release]
PHST- 2023/07/03 06:41 [pubmed]
PHST- 2023/07/03 06:41 [medline]
PHST- 2023/07/03 01:23 [entrez]
AID - jcsm.10592 [pii]
AID - JC2300026 [pii]
AID - 10.5664/jcsm.10592 [doi]
PST - ppublish
SO  - J Clin Sleep Med. 2023 Jul 1;19(7):1293-1302. doi: 10.5664/jcsm.10592.